Intusomics Analytics is a bioinformatics and omics research CRO based in Madrid. It was born from a specific experience: generating samples with great effort in the lab, then receiving a standard analysis that does not answer the study's question.
In many omics projects, a great deal is invested in samples and sequencing, and then the analysis is handled with a standard procedure, the same for every study. That is where subtle signals get lost: small effects, minority populations or cohorts with few samples, which are the norm in research.
Intusomics was created to change that last step. Each project is a commissioned scientific research engagement: it starts from a biological question, is designed around it and ends in results that can be published, patented or turned into a product.
The analysis is built from the hypothesis, the design and the sample type of each study.
Deep Learning models and proprietary algorithms to extract signal where standard methods fall short.
From study design to publication or patent, with the same scientist in charge.
Daniel Arenas González is the Founder and Scientific Director of Intusomics Analytics. He trained at the Universidad de Alcalá, where he built a broad foundation across the key areas of human health sciences. He then went on to develop a research career in Regenerative Medicine at the Instituto de Investigación Hospital Universitario 12 de Octubre (imas12), contributing to the development of mesenchymal stem cell therapies for multiple sclerosis and urinary incontinence under GMP conditions.
His profile combines wet-lab expertise with advanced computational analysis, designing and implementing omics data pipelines including bulk and single-cell RNA-seq, metagenomics and differential expression, working in high-performance computing environments. He previously collaborated as a bioinformatician with the Molecular Immunonutrition group at IMDEA Alimentación through a VIU–IMDEA research collaboration, applying transcriptomic analysis to precision nutrition intervention studies.
That dual experience, in the lab and in analysis, shapes the way Intusomics works: understanding how each sample was generated before analyzing it, and explaining the results in the language of whoever ran the experiment.
Every project has a scientist in charge who follows it through every stage, with full confidentiality over data and findings.
A first conversation about the biological question, the available samples and the goal.
Technique, sample size and controls are chosen with statistical power in mind, also when samples are scarce.
Generated with the right technology or taken from existing data, with quality checked before analysis.
Statistics tailored to the design and, when standard methods are not enough, Deep Learning models and proprietary algorithms.
Results are read in their biological context and discussed in a meeting with the scientist in charge.
Support with figures, methods and publication. If there is a valuable finding, the route to industrial property.
Part of Intusomics' activity is devoted to developing its own methods and tools. Some are already part of client projects:
Software to explore results without coding: search any gene or protein, compare groups and create interactive plots.
Exploring and filtering genomic variants from the browser, in a secure environment. See the launch.
A new methodology to discover microRNA biomarkers for diagnostic and therapeutic applications. In early access.
Analysis workflows are validated against public reference standards. The genomics and metagenomics validations are published in our Newsroom.
The Scientific Advisory Board brings together researchers in genomics, computational biology, clinical research and translational medicine, who review methods and guide new lines of work. Intusomics is also a member of ASEBIO, the Spanish Bioindustry Association.
First reply within 24–48 hours, with an initial assessment of what can be done.
Get in touch →